Uncover more about what may be driving r/m HNSCC in your patients
Head and neck squamous cell carcinoma (HNSCC), the 6th most common cancer worldwide, is driven by inherited or acquired genomic alterations—some of which are associated with a poorer prognosis.1,2
Biomarker testing can reveal inherited or acquired genomic alterations that may warrant a tailored treatment approach. Identifying these biomarkers in your patients can help your team to determine viable therapeutic options, including participation in ongoing clinical trials.1,2
Discover how you can uncover more for your HNSCC patients.
UNCOVER MORE ABOUT WHAT MAY BE DRIVING R/M HNSCC IN YOUR PATIENTS
Head and neck squamous cell carcinoma (HNSCC), the 6th most common cancer worldwide, is driven by inherited or acquired genomic alterations—some of which are associated with a poorer prognosis.1,2
Biomarker testing can reveal inherited or acquired genomic alterations that may warrant a tailored treatment approach. Identifying these biomarkers of significance in your patients can help your team to determine viable therapeutic options, including participation in ongoing clinical trials.1,2
Discover how you can uncover more for your HNSCC patients.